IHCH-7113

IHCH-7113
Clinical data
Drug classSerotonin 5-HT2A receptor agonist; Serotonergic psychedelic; Hallucinogen
Identifiers
  • (6bR,10aS)-3-methyl-2,3,6b,7,8,9,10,10a-octahydro-1H-pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxaline
CAS Number
PubChem CID
ChemSpider
UNII
Chemical and physical data
FormulaC14H19N3
Molar mass229.327 g·mol−1
3D model (JSmol)
  • CN1CCN2[C@H]3CCNC[C@H]3C4=C2C1=CC=C4
  • InChI=1S/C14H19N3/c1-16-7-8-17-12-5-6-15-9-11(12)10-3-2-4-13(16)14(10)17/h2-4,11-12,15H,5-9H2,1H3/t11-,12-/m0/s1
  • Key:QLGUCSLWLPCOTR-RYUDHWBXSA-N

IHCH-7113 is a serotonin 5-HT2A receptor agonist and serotonergic psychedelic of the pyridopyrroloquinoxaline family. It was derived by structural simplification of the serotonin 5-HT2A receptor antagonist and atypical antipsychotic lumateperone. Other related compounds include IHCH-7079 and IHCH-7086, which were found to be non-hallucinogenic biased serotonin 5-HT2A receptor agonists that were active in antidepressant assays but did not produce psychedelic-like responding in mice. IHCH-7113 on the other hand produced a head-twitch response comparable to that of DOI or LSD, which was blocked by the serotonin 5-HT2A receptor antagonist volinanserin.[1][2][3] The drug is not a controlled substance in the United States[4] or Canada.[5]

See also

References

  1. ^ Robichaud AJ, et al. Substituted heterocycle fused gamma-carbolines. Patent US 6552017
  2. ^ Tomesch JC, et al. Preparation of 4-((6BR,10AS)-3-methyl-2,3,6B,9,10, 10A-hexahydro-1H-pyrido[3′,4′:4,5]pyrrolo [1,2,3-de]quinoxalin-8-(7H)-yl)-1-(4-fluorophenyl)-1-butanone or a pharmaceutically acceptable salt thereof. Patent US 9315504
  3. ^ Cao D, Yu J, Wang H, Luo Z, Liu X, He L, et al. (January 2022). "Structure-based discovery of nonhallucinogenic psychedelic analogs". Science. 375 (6579): 403–411. Bibcode:2022Sci...375..403C. doi:10.1126/science.abl8615. PMID 35084960. S2CID 246360313.
  4. ^ Orange Book: List of Controlled Substances and Regulated Chemicals (January 2026) (PDF), United States: U.S. Department of Justice: Drug Enforcement Administration (DEA): Diversion Control Division, January 2026
  5. ^ "Controlled Drugs and Substances Act". Department of Justice Canada. 5 December 2025. Retrieved 20 January 2026.
This article is issued from Wikipedia. The text is available under Creative Commons Attribution-Share Alike 4.0 unless otherwise noted. Additional terms may apply for the media files.